Engineered immune cells target childhood blood cancers in new trial
NCT ID NCT04787263
Summary
This study is testing a treatment where a patient's own immune cells are collected, genetically modified in a lab to better recognize and attack cancer cells, and then infused back into the body. It is for children and young adults (ages 1-35) whose leukemia or lymphoma has come back or hasn't responded to standard treatments. The main goals are to find a safe dose and see if this cell therapy can put the cancer into remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IRCCS Ospedale Pediatrico Bambino Gesù
Roma, 00165, Italy
Conditions
Explore the condition pages connected to this study.